Skip to main content

Becton Dickinson Value Stock - Dividend - Research Selection

Becton dickinson

ISIN: US0758871091 , WKN: 857675

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women\'s health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Becton Dickinson & Co. stock underperforms Monday when compared to competitors despite daily gains

2026-01-05
Becton Dickinson & Co. stock underperforms Monday when compared to competitors despite daily gains

BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial

2026-01-05
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix™ Mesh laparotomy reinforcement case performed in Greece following the product's expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union.

RBC Sees Durable Growth Profile at Becton Dickinson (BDX), Raises Target

2026-01-02
Becton, Dickinson and Company (NYSE:BDX) is included among the 12 Best Income Stocks to Buy Now. On December 17, RBC Capital raised its price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $202 and kept a Sector Perform rating on the shares. The call came as part of a broader research note looking […]

An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 40% Undervalued

2026-01-02
Key Insights Using the 2 Stage Free Cash Flow to Equity, Becton Dickinson fair value estimate is US$325 Becton...

Best Dividend Aristocrats For January 2026

2025-12-31

ICU Medical: Difficult Transition, A More Interesting Company (Upgrade)

2025-12-30
ICU Medical stock is poised for growth and margin gains post-integration. Here's what investors need to know.

Becton Dickinson Insiders Added US$1.36m Of Stock To Their Holdings

2025-12-29
In the last year, multiple insiders have substantially increased their holdings of Becton, Dickinson and Company...

Best Dividend Kings: December 2025

2025-12-28
Discover 22 undervalued Dividend Kings with 10%+ expected returns. See which outperformed SPY and get dividend growth insights.

Dividend Champion, Contender, And Challenger Highlights: Week Of December 28

2025-12-26

Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth

2025-12-26
HOLX's GYN Surgical unit gains momentum as the demand for gynecological devices rises globally, driven by innovation, M&A and strong overseas adoption.